LifeArc Ventures invests in Maxion Therapeutics
Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
Seed funding will be used to scale the solution through the application of machine learning
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS
First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science
AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…
Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.
Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.
10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised…
LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further and faster.